Indeed, the combination of radiotherapy and a PARP inhibitor (Olaparib) significantly decreased cell survival by increasing DNA damage and cell death in accordance with recent reports describing a sensitizing effect of the PARP inhibitors Talazoparib and Niraparib in melanoma as well (51). Here, PARP1 is linked to melanoma.